Literature DB >> 1564514

The decrease of CD8-positive lymphocytes in Alzheimer's disease.

T Pirttilä1, S Mattinen, H Frey.   

Abstract

The aim of this study was to analyze the possible association of the changes in systemic immunity in the neurodegenerative diseases and in brain atrophy per se. Therefore we enumerated the numbers and proportions of the CD3-, CD4- and CD8-positive cells and B-lymphocytes in peripheral blood of 136 patients with various neurodegenerative disorders of the brain and 58 healthy age-matched controls. The selective decrease of the CD8-positive lymphocytes was demonstrated in the patients with Alzheimer's disease. In contrast, in the patients with brain atrophy of unknown origin and in the patients with vascular dementia the number of the CD8-positive cells tended to increase. The results suggest that brain degenerative changes are associated with changes in the systemic immunity and the changes are linked with the underlying disorder more than brain degeneration per se.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1564514     DOI: 10.1016/0022-510x(92)90284-r

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  19 in total

1.  Increased T-cell reactivity and elevated levels of CD8+ memory T-cells in Alzheimer's disease-patients and T-cell hyporeactivity in an Alzheimer's disease-mouse model: implications for immunotherapy.

Authors:  Katharina Schindowski; Anne Eckert; Jürgen Peters; Corinna Gorriz; Uta Schramm; Thomas Weinandi; Konrad Maurer; Lutz Frölich; Walter E Müller
Journal:  Neuromolecular Med       Date:  2007-10-26       Impact factor: 3.843

Review 2.  The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer's disease.

Authors:  Marina A Lynch
Journal:  Immunology       Date:  2014-03       Impact factor: 7.397

3.  Immunophenotypes in the circulation of patients with mild cognitive impairment.

Authors:  Shino Magaki; Steven M Yellon; Claudius Mueller; Wolff M Kirsch
Journal:  J Psychiatr Res       Date:  2007-02-23       Impact factor: 4.791

Review 4.  T Cells-Protective or Pathogenic in Alzheimer's Disease?

Authors:  Róisín M McManus; Kingston H G Mills; Marina A Lynch
Journal:  J Neuroimmune Pharmacol       Date:  2015-05-10       Impact factor: 4.147

Review 5.  Can peripheral leukocytes be used as Alzheimer's disease biomarkers?

Authors:  Kavon Rezai-Zadeh; David Gate; Christine A Szekely; Terrence Town
Journal:  Expert Rev Neurother       Date:  2009-11       Impact factor: 4.618

Review 6.  Psychiatric disorders in toxoplasma seropositive patients--the CD8 connection.

Authors:  Rajarshi Bhadra; Dustin A Cobb; Louis M Weiss; Imtiaz A Khan
Journal:  Schizophr Bull       Date:  2013-02-20       Impact factor: 9.306

7.  Decreased proportion of cytomegalovirus specific CD8 T-cells but no signs of general immunosenescence in Alzheimer's disease.

Authors:  Gabriel Westman; Anna-Karin Lidehall; Peetra Magnusson; Martin Ingelsson; Lena Kilander; Lars Lannfelt; Olle Korsgren; Britt-Marie Eriksson
Journal:  PLoS One       Date:  2013-10-14       Impact factor: 3.240

8.  IVIg protects the 3xTg-AD mouse model of Alzheimer's disease from memory deficit and Aβ pathology.

Authors:  Isabelle St-Amour; Isabelle Paré; Cyntia Tremblay; Katherine Coulombe; Renée Bazin; Frédéric Calon
Journal:  J Neuroinflammation       Date:  2014-03-22       Impact factor: 8.322

9.  S100A7, a novel Alzheimer's disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10.

Authors:  Weiping Qin; Lap Ho; Jun Wang; Elaine Peskind; Giulio Maria Pasinetti
Journal:  PLoS One       Date:  2009-01-13       Impact factor: 3.240

10.  Reduced β-amyloid pathology in an APP transgenic mouse model of Alzheimer's disease lacking functional B and T cells.

Authors:  Claudia Späni; Tobias Suter; Rebecca Derungs; Maria Teresa Ferretti; Tobias Welt; Fabian Wirth; Christoph Gericke; Roger M Nitsch; Luka Kulic
Journal:  Acta Neuropathol Commun       Date:  2015-11-11       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.